Overview

• A new blood test for colon cancer, showing 83% accuracy in detecting the disease, offers a promising alternative to traditional screening methods.
• The test, not yet FDA-approved, is already available in the U.S. for $895, with an FDA decision expected this year.
• Guardant Health's blood test requires a follow-up colonoscopy for abnormal results, potentially leading to additional costs.
• Experts emphasize the importance of screening options, as current compliance with recommended screenings is below the 80% goal.
• The blood test's performance is similar to stool-based tests but less sensitive than colonoscopies, which remain the gold standard.